BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...first-in-human clinical trial design for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...first-in-human clinical trial design for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra...
BioCentury | Feb 16, 2018
Clinical News

Sorrento, Yuhan JV to start Korean trials of anti-PD-L1 mAb

...I testing of STI-A1015 (IMC-001) to treat solid tumors. STI-A1015 is a mAb against PD-L1. ImmuneOncia Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...first-in-human clinical trial design for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...first-in-human clinical trial design for AK117.Arch Oncology Inc., ImmuneOncia Therapeutics Inc., Invenra...
BioCentury | Feb 16, 2018
Clinical News

Sorrento, Yuhan JV to start Korean trials of anti-PD-L1 mAb

...I testing of STI-A1015 (IMC-001) to treat solid tumors. STI-A1015 is a mAb against PD-L1. ImmuneOncia Therapeutics Inc....
Items per page:
1 - 3 of 3